Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
The global market for Gestational Trophoblastic Disease is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Gestational Trophoblastic Disease players cover Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited and Eli Lilly and Company, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This latest report provides a deep insight into the global Gestational Trophoblastic Disease market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Gestational Trophoblastic Disease market, with both quantitative and qualitative data, to help readers understand how the Gestational Trophoblastic Disease market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
The study segments the Gestational Trophoblastic Disease market and forecasts the market size by Type (Chemotherapy, Surgery and Radiation Therapy), by Application (Hospitals, Clinics, Cancer Research Institutes and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Segmentation by application
Cancer Research Institutes
Segmentation by region
Middle East & Africa
Major companies covered
Bristol Myers Squibb
Accord Healthcare Limited
Eli Lilly and Company
Chapter 1: Scope of Gestational Trophoblastic Disease, Research Methodology, etc.
Chapter 2: Executive Summary, global Gestational Trophoblastic Disease market size and CAGR, Gestational Trophoblastic Disease market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Gestational Trophoblastic Disease revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Gestational Trophoblastic Disease revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Gestational Trophoblastic Disease market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen and Merck KGaA, etc.
Chapter 14: Research Findings and Conclusion